|
[Objective ] To observe the cloth budesonide / formoterol powder inhaler ( Symbicort can Turbuhaler ) efficacy and safety of the treatment of bronchial asthma [ method ] of 30 cases diagnosed in patients with severe asthma to the letter will can Turbuhaler 160ug / 4.5ug / suction, suction / 2 times / day , not timely demand use , sharing 12 weeks . Self-control observation before inhalation and related indicators around the 12 - week changes in clinical symptoms , drug reactions and lung function after inhalation FEV 1 ( first second forced expiratory volume ) , FEV 1 % (FEV 1 percentage of predicted value percentage ) , PEF ( peak expiratory peak flow value ), PEF% (PEF % predicted value percentage ) ] . [Results ] through treatment can significantly improve the clinical symptoms , pulmonary function ; reduce airway hyperresponsiveness sex ( AHR ) . Before and after treatment the difference was statistically significant (P lt; 0.05), prompted a joint inhaled glucocorticoids (ICS) and long-acting beta 2 agonists (LABA) therapy can improve lung function , inhalation therapy , the longer , the better the effect . [ Conclusion] The use of Symbicort Turbuhaler in patients with severe asthma can control symptoms , improve lung function , with good adherence and minor adverse .
|